The acquisition includes Nimble's lead asset, an investigational oral peptide inhibitor in preclinical development for the ...

Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a ...

Ustekinumab-stba, manufactured by Celltrion, is expected to be marketed in the United States in February 2025.

The Food and Drug Administration (FDA) has approved Steqeyma ® (ustekinumab-stba), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases in adults and ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque ...

Managing psoriasis during winter can be challenging. Experts share essential tips, including hydration, gentle cleansing, ...

These strategies aim to achieve and maintain low disease activity or remission using personalised treatment plans. The ...

“The approval of new treatment option is welcome news for people living with certain chronic inflammatory conditions, such as ...

AbbVie and Nimble Therapeutics have announced an acquisition deal in which AbbVie will gain ownership of the company’s ...

The following is a summary of “Time to Loss of Disease Control Following Guselkumab Withdrawal in Relation to Initial Speed ...

In a subset of patients in a 48-week extension trial, the mean duration of the first treatment-free interval was ...

Mindera Health, a leader in precision medicine for dermatological conditions, today announced their participation in MultiPlan’s national PPO networks. Effective immediately, health plan members who ...